{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T23:54:10Z","timestamp":1789430050643,"version":"build-2803163510"},"reference-count":38,"publisher":"Consortium of Multiple Sclerosis Centers","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,3,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background:<\/jats:title><jats:p>Vitamin D deficiency is associated with increased disease activity in multiple sclerosis (MS), but its role in progressive MS has not been elucidated. The objective was to determine the correlation between vitamin D levels and visual parameters in primary progressive MS (PPMS) and secondary progressive MS (SPMS).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods:<\/jats:title><jats:p>Serum 25-hydroxyvitamin D (25[OH]D) and 25-hydroxyvitamin D3 (25[OH]D3) levels were obtained from the Secondary and Primary Progressive Ibudilast NeuroNEXT Trial in MS (SPRINT-MS). Visual function measurements and vitamin D associations were determined using the Pearson correlation and the generalized linear mixed model.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results:<\/jats:title><jats:p>The analysis included 258 patients (mean \u00b1 SD age of 55.6 \u00b1 7.3 years, 52.7% female, and 52.3% PPMS). Mean vitamin D values were above sufficiency and were similar between PPMS and SPMS (P = .47 and P = .31). There was no association between 25(OH)D3 levels and any visual markers, including peripapillary retinal nerve fiber layer thickness (Spearman r = \u22120.08), macular volume (r = \u22120.03), ganglion cell\u2013inner plexiform layer (r = \u22120.07), and 2.5% low-contrast visual acuity test (r = \u22120.10). No statistically significant associations between vitamin D levels and visual system measurements were detected in the PPMS and SPMS subgroups.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions:<\/jats:title><jats:p>Vitamin D levels were not associated with optical coherence tomography findings or low-contrast letter acuity in this group of patients with progressive MS.<\/jats:p><\/jats:sec>","DOI":"10.7224\/1537-2073.2020-005","type":"journal-article","created":{"date-parts":[[2020,4,28]],"date-time":"2020-04-28T13:29:49Z","timestamp":1588080589000},"page":"53-58","source":"Crossref","is-referenced-by-count":7,"title":["Vitamin D Levels and Visual System Measurements in Progressive Multiple Sclerosis"],"prefix":"10.7224","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1668-4753","authenticated-orcid":false,"given":"Justin R.","family":"Abbatemarco","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Fox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Bermel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Ontaneda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4242","published-online":{"date-parts":[[2020,4,28]]},"reference":[{"key":"2021041419545415100_i1537-2073-23-2-53-b1","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1002\/ana.23591","article-title":"Vitamin D status predicts new brain magnetic resonance imaging activity in multiple sclerosis","volume":"72","author":"Mowry","year":"2012","journal-title":"Ann Neurol."},{"key":"2021041419545415100_i1537-2073-23-2-53-b2","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1136\/jnnp-2011-301876","article-title":"A randomised, double blind, placebo controlled trial with vitamin D3 as an add on treatment to interferon beta-1b in patients with multiple sclerosis","volume":"83","author":"Soilu-Hanninen","year":"2012","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"2021041419545415100_i1537-2073-23-2-53-b3","doi-asserted-by":"crossref","first-page":"2832","DOI":"10.1001\/jama.296.23.2832","article-title":"Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis","volume":"296","author":"Munger","year":"2006","journal-title":"JAMA."},{"key":"2021041419545415100_i1537-2073-23-2-53-b4","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1002\/ana.22043","article-title":"Higher 25-hydroxyvitamin D is associated with lower relapse risk in multiple sclerosis","volume":"68","author":"Simpson","year":"2010","journal-title":"Ann Neurol."},{"key":"2021041419545415100_i1537-2073-23-2-53-b5","doi-asserted-by":"crossref","first-page":"e167","DOI":"10.1212\/NXI.0000000000000167","article-title":"Effect of vitamin D on MS activity by disease-modifying therapy class","volume":"2","author":"Rotstein","year":"2015","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"2021041419545415100_i1537-2073-23-2-53-b6","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1001\/jamaneurol.2015.2742","article-title":"Association of vitamin D levels with multiple sclerosis activity and progression in patients receiving interferon beta-1b","volume":"72","author":"Fitzgerald","year":"2015","journal-title":"JAMA Neurol."},{"key":"2021041419545415100_i1537-2073-23-2-53-b7","doi-asserted-by":"crossref","first-page":"e1906","DOI":"10.1212\/WNL.0000000000008445","article-title":"Randomized trial of daily high-dose vitamin D3 in patients with RRMS receiving subcutaneous interferon beta-1a","volume":"93","author":"Hupperts","year":"2019","journal-title":"Neurology."},{"key":"2021041419545415100_i1537-2073-23-2-53-b8","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1177\/1352458508094399","article-title":"Association of vitamin D metabolite levels with relapse rate and disability in multiple sclerosis","volume":"14","author":"Smolders","year":"2008","journal-title":"Mult Scler."},{"key":"2021041419545415100_i1537-2073-23-2-53-b9","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.jsbmb.2015.11.009","article-title":"A low vitamin D status at diagnosis is associated with an early conversion to secondary progressive multiple sclerosis","volume":"164","author":"Muris","year":"2016","journal-title":"J Steroid Biochem Mol Biol."},{"key":"2021041419545415100_i1537-2073-23-2-53-b10","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.maturitas.2016.04.002","article-title":"Circulating vitamin D concentration and age-related macular degeneration: systematic review and meta-analysis","volume":"88","author":"Annweiler","year":"2016","journal-title":"Maturitas."},{"key":"2021041419545415100_i1537-2073-23-2-53-b11","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1136\/jnnp.55.9.747","article-title":"The ocular manifestations of multiple sclerosis, 1: abnormalities of the afferent visual system","volume":"55","author":"McDonald","year":"1992","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"2021041419545415100_i1537-2073-23-2-53-b12","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1016\/j.jocn.2011.04.008","article-title":"Reduced retinal nerve fiber layer and macular thickness in patients with multiple sclerosis with no history of optic neuritis identified by the use of spectral domain high-definition optical coherence tomography","volume":"18","author":"Fjeldstad","year":"2011","journal-title":"J Clin Neurosci."},{"key":"2021041419545415100_i1537-2073-23-2-53-b13","doi-asserted-by":"crossref","first-page":"e527","DOI":"10.1212\/WNL.0000000000006873","article-title":"Optical coherence tomography is highly sensitive in detecting prior optic neuritis","volume":"92","author":"Xu","year":"2019","journal-title":"Neurology."},{"key":"2021041419545415100_i1537-2073-23-2-53-b14","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1212\/01.wnl.0000295995.46586.ae","article-title":"Retinal nerve fiber layer is associated with brain atrophy in multiple sclerosis","volume":"69","author":"Gordon-Lipkin","year":"2007","journal-title":"Neurology."},{"key":"2021041419545415100_i1537-2073-23-2-53-b15","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1097\/WNO.0000000000000057","article-title":"Retinal nerve fiber layer thickness, brain atrophy, and disability in multiple sclerosis patients","volume":"34","author":"Abalo-Lojo","year":"2014","journal-title":"J Neuroophthalmol."},{"key":"2021041419545415100_i1537-2073-23-2-53-b16","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1177\/1352458516637679","article-title":"Retinal degeneration in primary-progressive multiple sclerosis: a role for cortical lesions?","volume":"23","author":"Petracca","year":"2017","journal-title":"Mult Scler."},{"key":"2021041419545415100_i1537-2073-23-2-53-b17","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.cct.2016.08.009","article-title":"Design, rationale, and baseline characteristics of the randomized double-blind phase II clinical trial of ibudilast in progressive multiple sclerosis","volume":"50","author":"Fox","year":"2016","journal-title":"Contemp Clin Trials."},{"key":"2021041419545415100_i1537-2073-23-2-53-b18","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1002\/ana.22366","article-title":"Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria","volume":"69","author":"Polman","year":"2011","journal-title":"Ann Neurol."},{"key":"2021041419545415100_i1537-2073-23-2-53-b19","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.mri.2016.08.022","article-title":"Quantitative quality assurance in a multicenter HARDI clinical trial at 3T","volume":"35","author":"Zhou","year":"2017","journal-title":"Magn Reson Imaging."},{"key":"2021041419545415100_i1537-2073-23-2-53-b20","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.msard.2019.08.014","article-title":"Vitamin D and MRI measures in progressive multiple sclerosis","volume":"35","author":"Abbatemarco","year":"2019","journal-title":"Mult Scler Relat Disord."},{"key":"2021041419545415100_i1537-2073-23-2-53-b21","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1017\/S0007114512002851","article-title":"Long-term vitamin D3 supplementation is more effective than vitamin D2 in maintaining serum 25-hydroxyvitamin D status over the winter months","volume":"109","author":"Logan","year":"2013","journal-title":"Br J Nutr."},{"key":"2021041419545415100_i1537-2073-23-2-53-b22","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1007\/s00198-005-1867-7","article-title":"Estimates of optimal vitamin D status","volume":"16","author":"Dawson-Hughes","year":"2005","journal-title":"Osteoporos Int."},{"key":"2021041419545415100_i1537-2073-23-2-53-b23","doi-asserted-by":"crossref","first-page":"e0193070","DOI":"10.1371\/journal.pone.0193070","article-title":"Plasma 25-hydroxyvitamin D concentration and risk of type 2 diabetes and pre-diabetes: 12-year cohort study","volume":"13","author":"Park","year":"2018","journal-title":"PLoS One."},{"key":"2021041419545415100_i1537-2073-23-2-53-b24","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1007\/s00415-006-0315-8","article-title":"Vitamin D levels in people with multiple sclerosis and community controls in Tasmania, Australia","volume":"254","author":"van der Mei","year":"2007","journal-title":"J Neurol."},{"key":"2021041419545415100_i1537-2073-23-2-53-b25","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/S1474-4422(10)70086-7","article-title":"Vitamin D and multiple sclerosis","volume":"9","author":"Ascherio","year":"2010","journal-title":"Lancet Neurol."},{"key":"2021041419545415100_i1537-2073-23-2-53-b26","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1097\/00005072-199608000-00006","article-title":"1,25 Dihydroxyvitamin D3 exerts regional effects in the central nervous system during experimental allergic encephalomyelitis","volume":"55","author":"Nataf","year":"1996","journal-title":"J Neuropathol Exp Neurol."},{"key":"2021041419545415100_i1537-2073-23-2-53-b27","doi-asserted-by":"crossref","first-page":"e0156122","DOI":"10.1371\/journal.pone.0156122","article-title":"Vitamin D status does not affect disability progression of patients with multiple sclerosis over three year follow-up","volume":"11","author":"Muris","year":"2016","journal-title":"PLoS One."},{"key":"2021041419545415100_i1537-2073-23-2-53-b28","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1007\/s00415-010-5467-x","article-title":"A preliminary longitudinal study of the retinal nerve fiber layer in progressive multiple sclerosis","volume":"257","author":"Henderson","year":"2010","journal-title":"J Neurol."},{"key":"2021041419545415100_i1537-2073-23-2-53-b29","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1177\/1352458516642315","article-title":"A prospective cohort study of vitamin D in optic neuritis recovery","volume":"23","author":"Burton","year":"2017","journal-title":"Mult Scler."},{"key":"2021041419545415100_i1537-2073-23-2-53-b30","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1212\/WNL.0000000000000524","article-title":"Factors associated with recovery from acute optic neuritis in patients with multiple sclerosis","volume":"82","author":"Malik","year":"2014","journal-title":"Neurology."},{"key":"2021041419545415100_i1537-2073-23-2-53-b31","doi-asserted-by":"crossref","first-page":"372","DOI":"10.4103\/1735-1995.158266","article-title":"Effects of vitamin D on retinal nerve fiber layer in vitamin D deficient patients with optic neuritis: preliminary findings of a randomized, placebo-controlled trial","volume":"20","author":"Salari","year":"2015","journal-title":"J Res Med Sci."},{"key":"2021041419545415100_i1537-2073-23-2-53-b32","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1212\/WNL.0b013e3181e1cec2","article-title":"A phase I\/II dose-escalation trial of vitamin D3 and calcium in multiple sclerosis","volume":"74","author":"Burton","year":"2010","journal-title":"Neurology."},{"key":"2021041419545415100_i1537-2073-23-2-53-b33","doi-asserted-by":"crossref","first-page":"627","DOI":"10.3109\/08820139.2011.573041","article-title":"Therapeutic effect of vitamin D3 in multiple sclerosis patients","volume":"40","author":"Mosayebi","year":"2011","journal-title":"Immunol Invest."},{"key":"2021041419545415100_i1537-2073-23-2-53-b34","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1177\/1352458511434607","article-title":"Effect of vitamin D3 supplementation on relapses, disease progression, and measures of function in persons with multiple sclerosis: exploratory outcomes from a double-blind randomised controlled trial","volume":"18","author":"Kampman","year":"2012","journal-title":"Mult Scler."},{"key":"2021041419545415100_i1537-2073-23-2-53-b35","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1177\/1352458511418630","article-title":"Visual dysfunction in multiple sclerosis correlates better with optical coherence tomography derived estimates of macular ganglion cell layer thickness than peripapillary retinal nerve fiber layer thickness","volume":"17","author":"Saidha","year":"2011","journal-title":"Mult Scler."},{"key":"2021041419545415100_i1537-2073-23-2-53-b36","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1001\/archneurol.2009.230","article-title":"Macular volume determined by optical coherence tomography as a measure of neuronal loss in multiple sclerosis","volume":"66","author":"Burkholder","year":"2009","journal-title":"Arch Neurol."},{"issue":"pt 2","key":"2021041419545415100_i1537-2073-23-2-53-b37","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1093\/brain\/awr264","article-title":"Optical coherence tomography segmentation reveals ganglion cell layer pathology after optic neuritis","volume":"135","author":"Syc","year":"2012","journal-title":"Brain."},{"key":"2021041419545415100_i1537-2073-23-2-53-b38","article-title":"Inflammatory activity and vitamin D levels in an MS population treated with rituximab","volume":"5","author":"Linden","year":"2019","journal-title":"Mult Scler J Exp Transl Clin."}],"container-title":["International Journal of MS Care"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/meridian.allenpress.com\/ijmsc\/article-pdf\/23\/2\/53\/2810681\/i1537-2073-23-2-53.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/meridian.allenpress.com\/ijmsc\/article-pdf\/23\/2\/53\/2810681\/i1537-2073-23-2-53.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T21:12:05Z","timestamp":1752786725000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ijmsc.org\/view\/vitamin-d-levels-and-visual-system-measurements-in-progressive-multiple-sclerosis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,28]]},"references-count":38,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2020,4,28]]},"published-print":{"date-parts":[[2021,3,1]]}},"URL":"https:\/\/doi.org\/10.7224\/1537-2073.2020-005","relation":{},"ISSN":["1537-2073"],"issn-type":[{"value":"1537-2073","type":"print"}],"subject":[],"published":{"date-parts":[[2020,4,28]]}}}